The perioperative phase III Neotorch study in which stage II/III resectable NSCLC patients without EGFR/ALK alterations in non-squamous NSCLC received neoadjuvant toripalimab or placebo with chemotherapy for 3 cycles followed by toripalimab or placebo monotherapy for 13 cycles every 3 weeks after also showed favorable early findings with significant improvement of EFS in the toripalimab arm (HR = 0.40, 95% CI: 0.277–0.565, P < 0.0001) along with a significantly greater major pathologic complete response and pathologic response [54]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.